Skip to main content


Medicare's Evolution from Passive Payer to Value-Driven Purchaser of Healthcare
Health Policy in the New Administration
The Clinical and Economic Complexity of Biologics
Health Reform and the Next President
Policy Considerations in Evidence-Based Coverage Decisions
Part D under the Medicare Improvements for Patients and Providers Act of 2008
The Many Challenges of Pay-for-Performance Programs
Orphan Drugs: The Potential Impact of Generic Biologics
The Missing Quality Standard for Medication Adherence
Potential Benefits of Prediction Models from Large Electronic Databases
Page 4 of 4
Results 31 - 40 of 40